Deconstructing DTCA: Towards a differentiated policy response to Direct-to-Consumer Advertising in Australia.

处方药支出是医疗预算中增长最快的部分。近年来，人们的注意力转向了直接面向消费者的广告(DTCA)对消费者需求和药品成本的影响。虽然DTCA在澳大利亚是被禁止的，但很明显，不同类型的DTCA正在发生。这项研究将审查DTCA的性质和范围，审查DTCA的好处和危害，并确定主要利益相关者对DTCA的看法。这项研究将在一次国家讲习班上达到高潮，该讲习班将为应对不同类型和模式的DTCA制定一套不同的建议。这可能会导致更好的卫生政策和资源，以帮助消费者和卫生专业人员处理DTCA。

Spending on prescription pharmaceuticals is the fastest growing part of the health budget. In recent years attention has shifted to the impact of direct-to-consumer advertising (DTCA) on consumer demand and drug costs. Although DTCA is prohibited in Australia, it is clear that different types of DTCA are occurring. This study will examine the nature and range of DTCA, review the benefits and harms of DTCA, and identify the perspectives of major stakeholders regarding DTCA. The study will culminate in a national workshop which will develop a differentiated set of recommendations for responding to different types and modes of DTCA. This is likely to lead to better health policy and to resources that may assist consumers and health professionals deal with DTCA.